drugset / Trial / NCT00865371

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

NCT00865371

Phase 1 Completed 26 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg Extended-Release Tablet to that of Wellbutrin SR® 150 mg Tablet after a single, one-tablet dose in subjects fed a standard meal.

Timeline

Start
2004-09
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg

Indications

No indication recorded.